Amal Therapeutics raises seed round from Boehringer Ingelheim Venture Fund and High-Tech Gründerfonds

Geneva/Berlin/Ingelheim/Bonn, 20th February 2014. Amal Therapeutics SA, a Swiss and German-­based company focusing on the development of therapeutic cancer vaccines, announced today that it has closed its seed financing round. The funds will be used to consolidate the cell-­penetrating peptide based technology platform and progress the first vaccine candidate up to pre-­clinical development. The investment […]

Amal Therapeutics received the support from the “Eidgenössische Stiftung zur Förderung Schweizerische Volkswirtschaft durch wissenschaftlische Forschung”

Amal Therapeutics received the support from the “Eidgenössische Stiftung zur Förderung Schweizerische Volkswirtschaft durch wissenschaftlische Forschung”.

Amal Therapeutics received a CTI grant for a research project in collaboration with the Laboratory of Tumor Immunology, University of Geneva

Amal Therapeutics received a CTI grant for a research project in collaboration with the Laboratory of Tumor Immunology, University of Geneva.